YCBDNYSEPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends September 30
cbdMD, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.35−0.01 (-2.22%)
Close on Oct 19, 2026
- Market cap
- $3.70M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
62.4%−0.6 pts over 5 years
Operating margin
-11.3%+30.7 pts over 5 years
Net margin
-10.6%−40.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -1.5% | -18.5% | -14.5% | – | |
| Gross profit | -0.2% | -18.8% | -14.6% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 21.6% | -44.4% | |
| Return on assets | – | 12.3% | -19.4% | |
| Current ratio | 0.50 | 3.08 | 2.05 | |
| Debt to equity | – | 0.00 | – | |
| Net debt to EBITDA | – | 0.86× | – | |
| Interest coverage | -25.1× | – | – | |
| Inventory turnover | – | 3.1× | 2.6× | |
| Capex to revenue | 6.3% | 3.2% | 1.0% | |
| Diluted shares | 0M | 0M | 4M |
Where the cash went
Fiscal 2021 to 2025, five years combined
cbdMD generated $35.17M from operations and spent $4.26M on capital expenditure, dividends and share buybacks. 40% of that went back into the business.
Generated
$35.17M
Used
$4.26M
Capital expenditure$1.70M40%Dividends$2.55M60%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-10.6%
×Asset turnover1.83×
×Equity multiplier2.29×
=Return on equity, FY2025-44.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -10.6% | 1.83× | 2.29× | -44.4% |
| FY2024 | -19.0% | 1.46× | 2.44× | -67.3% |
| FY2023 | -95.0% | 0.85× | 1.41× | -113.4% |
| FY2022 | -198.0% | 0.43× | 1.23× | -104.2% |
| FY2021 | -52.6% | 0.38× | 1.29× | -25.7% |
| FY2020 | 30.1% | 0.41× | 1.76× | 21.6% |
| FY2019 | -217.1% | 0.43× | 2.12× | -199.0% |
| FY2018 | 13.7% | 0.04× | 1.21× | 0.7% |
| FY2017 | -31.0% | 1.03× | 1.90× | -60.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$2.04M
- Cash generatingOperating cash flow above zero-$1.45M
- Return on assets improvedROA up on the prior year-22.8% → -19.3%
- Earnings backed by cashOperating cash flow above net income-$1.45M vs -$2.04M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.74 → 2.05
- No dilutionShare count did not rise1M → 4M
- Gross margin improvedGross margin up on the prior year61.57% → 62.37%
- More efficientAsset turnover rose1.20 → 1.81